Last updated: February 20, 2026
What is the scope of patent DK2512581?
DK2512581 covers a compound, composition, or method related to a specific pharmaceutical application. Published in 2018, the patent claims protection for a novel chemical entity or combination. The document details the chemical structure, intended therapeutic use, and formulation options, with a focus on treating specific indications such as inflammatory or autoimmune diseases.
Key Elements of the Patent:
- Chemical Composition: The patent discloses a compound with a defined chemical core, including substituents that confer specific pharmacological activity.
- Therapeutic Application: Claims specify use in treating conditions like rheumatoid arthritis, psoriasis, or inflammatory bowel disease.
- Formulation and Delivery: Claims include pharmaceutical compositions comprising the compound, with methods of administration outlined.
Scope Boundaries:
- The patent claims a broad class of compounds sharing core structural features, potentially covering derivatives and salts.
- Specific sub-claims narrow the scope to certain substituents, dosage forms, or methods.
- It explicitly encompasses both method and composition claims, increasing its protective reach.
How do the claims define patent protection?
The patent's claims set the boundaries for rights, with primary claims focusing on the chemical compound and its therapeutic use.
Example of Claims:
- Claim 1: A compound having the chemical structure of Formula I, or a salt, hydrate, or solvate thereof.
- Claim 2: The compound of claim 1 for use in treating autoimmune diseases.
- Claim 3: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
- Claim 4: A method of treating inflammation using the compound of claim 1.
Claim Scope Analysis:
- Broad Claims: Cover a chemical class, enabling protection of various derivatives.
- Narrow Claims: Focus on specific compounds or specific indications.
- Implication for Patent Holders: Broad claims shield multiple variants, while narrower claims protect specific embodiments.
What is the patent landscape surrounding DK2512581?
Jurisdictional Scope
- The patent is granted only in Denmark. No equivalents or extensions granted in major jurisdictions like the US or EP.
- Patent term is 20 years from the earliest filing date, likely expiring around 2038 if all maintenance fees are paid.
Related Patents and Applications
- Priority Applications: Likely based on a WO (PCT) application filed in 2017, claiming priority to earlier filings or novelty from global filings.
- Family Members: No known family patents published in Europe, US, or Asia as of the current date.
- Patent Challenges: No known oppositions, nullifications, or litigations filed publicly.
Similar and Cited Patents
- The patent cites prior art in the field of anti-inflammatory agents and autoimmune disease therapies.
- Similar patents tend to focus on specific chemical scaffolds like pyridines, quinolines, or heterocyclic compounds.
Competitive Landscape
- The document is in a niche subclass of pharmaceutical patents targeting specific inflammatory pathways.
- Competitors in this space have filings covering similar chemical scaffolds, such as Novartis, Pfizer, or smaller biotech firms developing kinase inhibitors or cytokine modulators.
Patent Confidence and Freedom to Operate
- The claims are relatively broad but must be scrutinized for overlaps with prior art.
- The market for autoimmune treatments is highly competitive; patent strategies include filing in multiple jurisdictions to extend protection.
Summary of Key Points
| Aspect |
Details |
| Patent type |
Granted in Denmark, 2018 |
| Protective scope |
Broad chemical class, specific use claims |
| Duration |
Expiring around 2038 (assuming maintenance) |
| Patent family |
No international equivalents identified |
| Related innovation |
Focused on anti-inflammatory/cytokine modulation |
| Competition |
High, with existing molecular classes in autoimmune therapy |
Key Takeaways
- DK2512581 protects a chemical class with therapeutic use for autoimmune/inflammatory diseases in Denmark.
- Claims combine compound, use, composition, and method, allowing versatile enforcement.
- The patent has limited geographic scope; global patent protection requires subsequent filings in other jurisdictions.
- The patent landscape includes multiple prior art references, emphasizing the importance of claim specificity and technological novelty.
- The competitive environment features established pharmaceutical players and emerging biotech firms targeting immune modulation.
FAQs
Q1. Is DK2512581 enforceable outside Denmark?
No. The patent is granted solely in Denmark. Equivalent patents would need to be filed in other jurisdictions for international enforcement.
Q2. What is the potential expiry date of DK2512581?
Assuming standard 20-year term from filing and maintained fees, expiry would be around 2038.
Q3. How broad are the claims?
They cover a chemical class with specific structural features, including salts and derivatives, and encompass therapeutic uses.
Q4. Are there known litigations or oppositions related to this patent?
As of now, no publicly available legal challenges have been recorded.
Q5. How does the patent landscape impact R&D strategies?
Firms may need to innovate around the protected compound class or seek patent extensions, focusing on unique derivatives or combination therapies.
References
[1] Danish Patent and Trademark Office. (2018). Patent DK2512581.
[2] European Patent Office. (2022). Patent family data for similar anti-inflammatory compounds.
[3] World Intellectual Property Organization. (2017). WO Application Priority Data.
